A 62-year-old woman from Mumbai presents with a 4-month history of persistent epigastric pain, anorexia, and vomiting. She has a remote history of partial gastrectomy for peptic ulcer disease 25 years ago. Upper endoscopy reveals a 5 cm infiltrative lesion at the gastric cardia with involvement of the gastroesophageal junction. Biopsy confirms signet-ring cell adenocarcinoma. CT chest and abdomen shows no distant metastases, but there is extensive thickening of the proximal stomach wall with involvement of the left gastric and celiac lymph nodes (T4aN2M0). What is the most appropriate surgical approach?

Explanation

## Surgical Management of Cardia Gastric Cancer with Signet-Ring Histology (T4aN2M0) ### Tumour Characteristics and Surgical Implications **Key Point:** This patient has three features that mandate total gastrectomy: 1. **Location at cardia/GEJ**: Proximal gastric tumours require total gastrectomy to achieve adequate proximal margins (≥5 cm). 2. **Signet-ring cell (diffuse-type) histology**: Signet-ring cancers have a propensity for intramural spread and multifocal involvement; total gastrectomy is standard [cite:Japanese Gastric Cancer Association Guidelines 5e]. 3. **T4a disease with extensive wall thickening**: Transmural invasion with possible serosal involvement necessitates en bloc resection of adjacent structures if feasible. ### Why Total Gastrectomy Is Necessary **High-Yield:** Total gastrectomy is indicated for: - Cardia/proximal gastric tumours (inadequate margin with distal gastrectomy) - Diffuse-type histology (signet-ring, linitis plastica) - Tumours with extensive intramural spread - Tumours crossing the GEJ Distal gastrectomy would leave proximal stomach with high risk of residual disease in signet-ring cancer. ### Distal Esophagectomy Rationale **Clinical Pearl:** When a cardia tumour involves the GEJ and extends into the distal esophagus (as suggested by "involvement of the gastroesophageal junction"), distal esophagectomy (typically 3–5 cm of esophagus) is performed to achieve adequate proximal margin and reduce anastomotic recurrence risk. ### Reconstruction: Roux-en-Y Esophagojejunostomy **Mnemonic:** **Total gastrectomy = Roux-en-Y** — After total gastrectomy, a Roux-en-Y (esophagojejunostomy with a 40–50 cm afferent limb) is the standard reconstruction. This: - Prevents bile reflux into the esophagus - Reduces risk of reflux esophagitis and anastomotic ulceration - Is superior to simple esophagogastrostomy in terms of quality of life ### D2 Lymphadenectomy **Key Point:** D2 lymphadenectomy (removal of perigastric and second-tier nodes including left gastric, celiac, and splenic nodes) is standard for curative-intent surgery in locally advanced gastric cancer. The patient has N2 disease (involvement of second-tier nodes), making D2 dissection essential. ### Staging and Curative Intent T4aN2M0 is AJCC Stage IIIC (locally advanced, resectable). Absence of distant metastases and peritoneal carcinomatosis makes surgery with curative intent appropriate. Adjuvant chemotherapy (capecitabine + oxaliplatin or 5-FU-based regimen) is indicated postoperatively if R0 resection is achieved. ### Comparison of Surgical Approaches for Cardia Cancer | Approach | Indication | Outcome | Error | | --- | --- | --- | --- | | Distal gastrectomy | Distal/antral tumours | Adequate margin, better QoL | **Wrong for cardia/signet-ring** | | Total gastrectomy + distal esophagectomy | Cardia/GEJ tumours, diffuse histology | Adequate proximal margin, lower recurrence | **Correct for this case** | | Palliative bypass | Unresectable/M1 disease | Symptom relief only | **Wrong — patient is resectable** | | Neoadjuvant chemo alone | Borderline resectable after restaging | May downstage; reassess operability | **Premature — patient is resectable now** | **Warning:** Signet-ring cell carcinoma has a worse prognosis than intestinal-type adenocarcinoma, but this does NOT preclude curative surgery if M0 and resectable. Neoadjuvant chemotherapy may be considered in select cases (e.g., T4b, bulky N3 disease), but this patient's T4aN2M0 status supports upfront surgery.